SWOG clinical trial number
SWOG-8609

VM-26 (Teniposide) Single Drug Treatment for Extensive Small Cell Lung Cancer

Closed
Phase
Accrual
90%
Published
Abbreviated Title
VM-26 (Teniposide) Single Drug Treatment for Extensive Small Cell Lung Cancer
Activated
09/15/1988
Closed
11/15/1990

Research committees

Lung Cancer

Publication Information Expand/Collapse

1997

Teniposide (VM-26) as a single drug treatment for patientss with extensive small cell lung carcinoma. A Phase II study of the Southwest Oncology Group.

PN Grozea;JJ Crowley;VA Canfield;L Kingsbury;SW Ross;GS Beltran;LR Laufman;GR Weiss;RB Livingston Cancer 80(6):1029-1033

1994

SWOG 8609 - a phase II trial of teniposide (VM-26) as therapy for extensive small cell lung cancer (SCLC)

V Canfield;P Grozea;J Crowley;R Livingston Lung Cancer 11(Suppl.1):102(#389)

Other Clinical Trials

SWOG Clinical Trial Number
S2302

PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
95%
Open
Phase
SWOG Clinical Trial Number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open